Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 19/20 | 0.61 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.61 |
| ▸ | GCGR | P47871 | 1/20 | 0.60 |
| ▸ | GIPR | P48546 | 1/20 | 0.60 |
| ▸ | CCKBR | P32239 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30524411 | 0.95 | GLP1R (0.59) | GLP1RGCGRGIPR | |
| SCHEMBL31574195 | 0.93 | GLP1R (0.63) | GLP1RPTH1RGCGRGIPRCCKBR | |
| SCHEMBL29565282 | 0.93 | GLP1R (0.60) | GLP1RPTH1RGCGRGIPR | |
| SCHEMBL31376429 | 0.93 | PTH1R (0.60) | GLP1RPTH1RGCGRGIPR | |
| SCHEMBL29973140 | 0.91 | CALCR (0.61) | GLP1RPTH1RCCKBR | |
| SCHEMBL30576939 | 0.91 | PTH1R (0.65) | GLP1RPTH1RGCGRGIPRCCKBR | |
| SCHEMBL29743000 | 0.90 | GLP1R (0.63) | GLP1RCCKBR | |
| SCHEMBL31038685 | 0.90 | PTH1R (0.62) | GLP1RPTH1RCCKBR | |
| SCHEMBL29973297 | 0.90 | GLP1R (0.62) | GLP1RCCKBR | |
| SCHEMBL30358209 | 0.90 | GLP1R (0.74) | GLP1RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629406-B2 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | MIDWESTERN UNIVERSITY (US) | 2026-05-19 | — | — | US | claimed |
| EP-4642536-A2 | COMPOSITION AND METHOD FOR WOUND HEALING AND REPAIR OF DAMAGED NERVES | Pharmazz, Inc. (US) | 2025-11-05 | — | — | EP | claimed |
| US-20240382461-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF HEARING LOSS | PHARMAZZ, INC. (US) | 2024-11-21 | — | — | US | claimed |
| WO-2024145197-A2 | COMPOSITION AND METHOD FOR WOUND HEALING AND REPAIR OF DAMAGED NERVES | PHARMAZZ, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| US-20240207356-A1 | COMPOSITION AND METHOD FOR WOUND HEALING AND REPAIR OF DAMAGED NERVES | PHARMAZZ, INC. (US) | 2024-06-27 | — | — | US | claimed |
| EP-4364811-A2 | ALTERATIONS IN ENDOTHELIN RECEPTORS FOLLOWING HEMORRHAGE AND RESUSCITATION BY CENTHAQUIN | Midwestern University (US) | 2024-05-08 | — | — | EP | claimed |
| EP-3813942-B1 | COMPOSITION COMPRISING CENTHAQUIN OR A SALT THEREOF FOR USE IN TREATING AN INDIVIDUAL SUFFERING ACUTE KIDNEY FUNCTION DECLINE | UNIV MIDWESTERN (US) | 2024-04-17 | — | — | EP | claimed |
| US-12629406-B2 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | MIDWESTERN UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130858-A1 | LYOPHILIZED SOVATELTIDE-BASED INJECTABLE FORMULATION AND A PROCESS FOR PREPARATION | PHARMAZZ INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4713094-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF HEARING LOSS | Pharmazz, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238297-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF HEARING LOSS | PHARMAZZ, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240382461-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF HEARING LOSS | PHARMAZZ, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4364811-A2 | ALTERATIONS IN ENDOTHELIN RECEPTORS FOLLOWING HEMORRHAGE AND RESUSCITATION BY CENTHAQUIN | Midwestern University (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-3813942-B1 | COMPOSITION COMPRISING CENTHAQUIN OR A SALT THEREOF FOR USE IN TREATING AN INDIVIDUAL SUFFERING ACUTE KIDNEY FUNCTION DECLINE | UNIV MIDWESTERN (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4067370-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE RELATED COMPOUNDS | Yu, Chongxi (US) | 2022-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629406-B2 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin | EDNRB, ADRA2B, ADRB2 | GLP1R 931/4885PTH1R 908/4885GCGR 808/4885 |
| US-20260130858-A1 | LYOPHILIZED SOVATELTIDE-BASED INJECTABLE FORMULATION AND A PROCESS FOR PREPARATION | SLC5A11, AQP4, SORD | GLP1R 1317/4885PTH1R 614/4885GCGR 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.